SCHEMBL20028059

SCHEMBL20028059

COC(=O)c1cc(C)nn1-c1ccc(CNC(=O)Cc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
NPC1 O15118 1/20 0.53
ALDH1A1 P00352 6/20 0.50
TP53 P04637 1/20 0.48
HPGD P15428 1/20 0.48
LMNA P02545 2/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
RAB9A P51151 1/20 0.47
GAA P10253 1/20 0.47
MALT1 Q9UDY8 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
P2RX7 Q99572 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20028060 0.90 MAPT (0.60) MAPTNPC1ALDH1A1LMNAMEN1
SCHEMBL22896939 0.89 MAPT (0.55) MAPTALDH1A1TP53HPGDLMNA
SCHEMBL20028140 0.86 MAPT (0.64) MAPTALDH1A1TP53HPGDMEN1
SCHEMBL22896512 0.85 MAPT (0.55) MAPTALDH1A1TP53HPGDKMT2A
SCHEMBL20028202 0.84 MAPT (0.55) MAPTALDH1A1TP53HPGDKMT2A
SCHEMBL20028525 0.84 MAPT (0.55) MAPTALDH1A1TP53HPGDKMT2A
SCHEMBL20028050 0.82 KMT2A (0.52) MAPTALDH1A1TP53LMNAMEN1
SCHEMBL20027618 0.81 MAPT (0.52) MAPTALDH1A1TP53HPGDLMNA
SCHEMBL28825868 0.81 ALDH1A1 (0.62) MAPTALDH1A1HPGDKMT2AL3MBTL1
SCHEMBL20027869 0.80 MAPT (0.52) MAPTALDH1A1KMT2AL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 MAPT 562/4885NPC1 2197/4885ALDH1A1 4193/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 MAPT 330/4885NPC1 1945/4885ALDH1A1 4421/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 MAPT 562/4885NPC1 2197/4885ALDH1A1 4193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.